Mounjaro 2,5; 5; 7,5; 10; 12,5 & 15 mg Solution for Injection
PDF Leaflet Revision Date: 09 December 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of type 2 diabetes and weight management.
Dosage (summary)
Starting dose: 2.5 mg once weekly, increase to 5 mg after 4 weeks; max 15 mg weekly.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Insulin secretagogues
- Oral contraceptives
Contraindications
- Hypersensitivity to tirzepatide
- Personal/family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
Common side effects
- Nausea
- Diarrhoea
- Vomiting
- Hypoglycaemia
Counselling Points
- Monitor for signs of thyroid tumours
- Stay hydrated to avoid dehydration
- Rotate injection sites
Serious warnings
- Risk of thyroid C-cell tumours
- Acute pancreatitis
- Gastrointestinal effects
Important Disclaimer
The Mounjaro 2,5; 5; 7,5; 10; 12,5 & 15 mg Solution for Injection professional information leaflet below is the property of Eli Lilly (SA) and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
